In Vitro Inhibition of Angiogenesis by Antibodies Directed against the 37kDa/67kDa Laminin Receptor
Da Costa Dias, B
Public Library of Science
The 37kDa/67kDa laminin receptor (LRP/LR) is a central receptor mediating interactions between tumour cells and the basement membrane and is thereby a key player in adhesion and invasion, essential processes in metastatic cancer. To affect continued tumour growth, tumours induce angiogenesis for the constant delivery of nutrients and oxygen. This study aims to determine the blocking effect of the anti-LRP/LR specific antibody, W3 on the angiogenic potential of HUVE (human umbilical vein endothelial) cells. Flow cytometric analysis revealed that 97% of HUVE cells display cell surface LRP/LR. An angiogenesis assay was conducted employing HUVE cells seeded on the basement membrane reconstituent Matrigel™ supplemented with the pro-angiogenic factor vascular endothelial growth factor (VEGF). Post 18h incubation at 37°C tubular structures, namely tube lengths were assessed. Treatment of established tubular structures with 100 μg/ml anti-LRP/LR specific antibody completely blocked angiogenesis. Our findings suggest a central role of the 37kDa/67kDa LRP/LR in tube formation and recommends anti-LRP/LR specific antibodies as potential therapeutic tools for treatment of tumour angiogenesis.
laminin receptor, matrigel, polyclonal antibody, unclassified drug, vasculotropin, W3 antibody, antiangiogenic activity, antibody specificity, basement membrane, cancer cell, Angiogenesis Inhibitors, Antibodies, Monoclonal, Antigens, CD31, Cell Membrane, Cells, Cultured, Human Umbilical Vein Endothelial Cells, Humans, Neovascularization, Physiologic, Receptors, Laminin, Vascular Endothelial Growth Factor A
Khusal, R. et al. 2013. In Vitro Inhibition of Angiogenesis by Antibodies Directed against the 37kDa/67kDa Laminin Receptor. PLoS ONE 8(3):e58888